Literature DB >> 12740467

US of the peritoneum.

Anthony E Hanbidge1, Deirdre Lynch, Stephanie R Wilson.   

Abstract

Familiarity with the pathophysiology of peritoneal disease is the basis of successful ultrasound (US) study of the peritoneum. The pouch of Douglas, diaphragmatic surfaces, the paracolic gutters, and the regions of the mesentery and omentum should receive careful scrutiny in the patient at risk for a peritoneal disease process. An optimal US technique requires assessment of the entire peritoneum with a transducer selected to reflect the depth of the region of interest. US may demonstrate minute quantities of free intraperitoneal fluid and is therefore capable of providing sensitive quantitative information about ascites. Qualitative information may also be inferred, as blood, pus, and neoplastic cells demonstrate correlation with particulate ascites on gray-scale US scans. Peritoneal nodules, plaques, and thickening may be detected on the visceral or parietal peritoneal surfaces, especially when high-frequency probes are used. Transvaginal study in women increases the sensitivity of US for detection of peritoneal disease. In women who have unexplained sepsis or are at risk for carcinomatosis, transvaginal scanning should routinely be added to the regular abdominal and pelvic studies regardless of the findings of those studies. Peritoneal carcinomatosis, primary peritoneal neoplasms, pseudomyxoma peritonei, and peritonitis have characteristic appearances at US.

Entities:  

Mesh:

Year:  2003        PMID: 12740467     DOI: 10.1148/rg.233025712

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  21 in total

1.  Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Authors:  Tracy R Daniels; Richard K Leuchter; Rafaela Quintero; Gustavo Helguera; José A Rodríguez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-11-30       Impact factor: 6.968

2.  Ultrasound Elastography for Differentiating Benign from Malignant Thickened Greater Omentum.

Authors:  Yixia Zhang; Xuemei Wang; Chunmei Tao; Yanhong Que; Wenjing Zhao; Bo Chen
Journal:  Eur Radiol       Date:  2015-09-29       Impact factor: 5.315

3.  Phase-inversion tissue harmonic imaging compared to fundamental B-mode ultrasound in the evaluation of the pathology of large and small bowel.

Authors:  T Schmidt; C Hohl; P Haage; D Honnef; A H Mahnken; G Krombach; W Piroth; R W Günther
Journal:  Eur Radiol       Date:  2005-04-08       Impact factor: 5.315

4.  Sonographic diagnosis of pneumoperitoneum using the 'enhancement of the peritoneal stripe sign.' A prospective study.

Authors:  Ashwin Asrani
Journal:  Emerg Radiol       Date:  2007-03-09

5.  Ultrasound-guided CAPD catheter insertion.

Authors:  Vishal Golay; Mayuri Trivedi; Arpita Roychowdhary; Puneet Arora; Dipankar Sarkar; Ametashver Singh; Sanjay Dasgupta; Rajendra Pandey
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

6.  Ultrasound findings in the omental bursa: a short pictorial essay.

Authors:  S Alessi; C Bortolotto; Luisa Carone
Journal:  J Ultrasound       Date:  2013-09-21

Review 7.  Ascites matters.

Authors:  Velauthan Rudralingam; Clare Footitt; Ben Layton
Journal:  Ultrasound       Date:  2016-12-01

8.  Sclerosing encapsulating peritonitis (cocoon bowel) presenting after laparotomy for splenic abscess.

Authors:  Jason Caldwell; Andrew Dyer
Journal:  J Radiol Case Rep       Date:  2013-10-01

Review 9.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

Review 10.  Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Authors:  Abdullah Al Shoyaib; Sabrina Rahman Archie; Vardan T Karamyan
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.